PMID- 38155713
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231230
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 14
DP  - 2023
TI  - First case report of a novel KIF13A-ALK fusion in a lung adenocarcinoma patient 
      and response to alectinib with a 4-year follow-up.
PG  - 1289346
LID - 10.3389/fgene.2023.1289346 [doi]
LID - 1289346
AB  - The prevalence of Anaplastic Lymphoma Kinase gene (ALK) fusion is about 5% among 
      patients with lung adenocarcinoma, underscoring the importance of pinpointing 
      distinct fusion variants for optimizing treatment approaches. This is the first 
      reported case of a 74-year-old female with stage IV lung adenocarcinoma, 
      featuring a novel Kinesin Family Member 13A (KIF13A)-ALK fusion, identified via 
      next-generation sequencing (NGS) and confirmed with fluorescence in situ 
      hybridization (FISH). Initially undergoing chemotherapy and then crizotinib, she 
      achieved a partial response (PR) before progressing with multiple bone 
      metastases. However, subsequent treatment with alectinib as a third-line option 
      yielded positive results. A stable disease state persisted for an impressive 
      31 months of progression-free survival (PFS), accompanied by minimal toxicity 
      symptoms. Up until now, a remarkable near 4-year span of overall survival (OS) 
      has been consistently observed and monitored. This report of a KIF13A-ALK fusion 
      case benefit significantly from alectinib with extensive follow-up. The case 
      diversifies the array of ALK fusion partners and holds clinical relevance in 
      refining therapeutic choices for KIF13A-ALK fusion-associated lung cancer.
CI  - Copyright (c) 2023 Mo, Cai, Yao, Zhao, Zhang, Liu and Mu.
FAU - Mo, Zheng
AU  - Mo Z
AD  - Department of Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical 
      Medicine, Tsinghua University, Beijing, China.
FAU - Cai, Cunliang
AU  - Cai C
AD  - Department of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung 
      Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Yao, Jingjing
AU  - Yao J
AD  - Department of Pathology, Beijing Tsinghua Changgung Hospital, School of Clinical 
      Medicine, Tsinghua University, Beijing, China.
FAU - Zhao, Jingquan
AU  - Zhao J
AD  - Department of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung 
      Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Zhang, Mingqiang
AU  - Zhang M
AD  - Department of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung 
      Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Liu, Hao
AU  - Liu H
AD  - Department of Pathology, Beijing Tsinghua Changgung Hospital, School of Clinical 
      Medicine, Tsinghua University, Beijing, China.
FAU - Mu, Xiangdong
AU  - Mu X
AD  - Department of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung 
      Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20231213
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC10753796
OTO - NOTNLM
OT  - alectinib
OT  - anaplastic lymphoma kinase (ALK fusion)
OT  - case report
OT  - kinesin family member 13A (KIF13A)
OT  - lung adenocarcinoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/02 10:02
MHDA- 2024/01/02 10:03
PMCR- 2023/12/13
CRDT- 2023/12/29 03:36
PHST- 2023/09/05 00:00 [received]
PHST- 2023/12/01 00:00 [accepted]
PHST- 2024/01/02 10:03 [medline]
PHST- 2024/01/02 10:02 [pubmed]
PHST- 2023/12/29 03:36 [entrez]
PHST- 2023/12/13 00:00 [pmc-release]
AID - 1289346 [pii]
AID - 10.3389/fgene.2023.1289346 [doi]
PST - epublish
SO  - Front Genet. 2023 Dec 13;14:1289346. doi: 10.3389/fgene.2023.1289346. eCollection 
      2023.